Regulation of drug metabolism and transporters

Current Drug Metabolism

Volumn 10, Issue 8, 2009, Pages 932-945

  Muntané, Jordi ^a,b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Conjugating enzymes; Cytochrome P450; Drug metabolizing enzymes; Gene regulation; Nuclear receptors; Orphan nuclear receptors; Transporters

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CELL NUCLEUS RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450; DRUG METABOLIZING ENZYME; FARNESOID X RECEPTOR; GLUCURONIC ACID; GLUTATHIONE; HEPATOCYTE NUCLEAR FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LIVER X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PREGNANE X RECEPTOR; RETINOID X RECEPTOR; STEROID RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NRF2; VITAMIN D RECEPTOR;

CONJUGATION; DRUG METABOLISM; DRUG TRANSPORT; ENZYME METABOLISM; ENZYME REGULATION; GENE CONTROL; HUMAN; HYDROPHILICITY; HYDROXYLATION; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; MODULATION; NONHUMAN; PROTEIN INTERACTION; PROTEIN TRANSPORT; REVIEW;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; MEMBRANE TRANSPORT PROTEINS; METABOLIC DETOXICATION, DRUG; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 74249102458     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009790274595     Document Type: Review

References (176)

1. Guengerich, F.P. Cytochromes P450, drugs, and diseases. Mol. Interv., 2003, 3(4), 194-204.
2. Lewis, D.F. P450 structures and oxidative metabolism of xenobiotics. Pharmacogenomics, 2003, 4(4), 387-395.
3. Hinson, J.A.; Forkert, P.G. Phase II enzymes and bioactivation. Can. J. Physiol. Pharmacol., 1995, 73(10), 1407-1413.
4. Xu, C.; Li, C.Y.; Kong, A.N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res., 2005, 28(3), 249-268.
5. Mizuno, N.; Niwa, T.; Yotsumoto, Y.; Sugiyama, Y. Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev., 2003, 55(3), 425-461.
6. Shitara, Y.; Sugiyama, D.; Kusuhara, H.; Kato, Y.; Abe, T.; Meier, P.J.; Itoh, T.; Sugiyama, Y. Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm. Res., 2002, 19(2), 147-153.
7. Byers, T.; Perry, G. Dietary carotenes, vitamin C, and vitamin E as protective antioxidants in human cancers. Annu. Rev. Nutr., 1992, 12, 139-159.
8. Kumar, A.; Takada, Y.; Boriek, A.M.; Aggarwal, B.B. Nuclear factor-kappaB: its role in health and disease. J. Mol. Med., 2004, 82(7), 434-448.
9. Zordoky, B.N.; El-Kadi, A.O. Role of NF-kappaB in the regulation of cytochrome P450 enzymes. Curr. Drug Metab., 2009, 10(2), 164-178.
10. Ben-Neriah, Y.; Schmitz, M.L. Of mice and men. EMBO Rep., 2004, 5(7), 668-673.
11. Rana, B.; Mischoulon, D.; Xie, Y.; Bucher, N.L.; Farmer, S.R. Cell-extracellular matrix interactions can regulate the switch between growth and differentiation in rat hepatocytes: reciprocal expression of C/EBP alpha and immediate-early growth response transcription factors. Mol. Cell. Biol., 1994, 14(9), 5858-5869.
12. Descombes, P.; Schibler, U. A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell, 1991, 67(3), 569-579.
13. An, M.R.; Hsieh, C.C.; Reisner, P.D.; Rabek, J.P.; Scott, S.G.; Kuninger, D.T.; Papaconstantinou, J. Evidence for posttranscriptional regulation of C/EBPalpha and C/EBPbeta isoform expression during the lipopolysaccharide- mediated acutephase response. Mol. Cell. Biol., 1996, 16(5), 2295-2306.
14. Wang, H.; LeCluyse, E.L. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin. Pharmacokinet., 2003, 42(15), 1331-1357.
15. De Bosscher, K.; Vanden Berghe, W.; Haegeman, G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev., 2003, 24(4), 488-522.
16. Adcock, I.M. Glucocorticoid-regulated transcription factors. Pulm. Pharmacol. Ther., 2001, 14(3), 211-219.
17. Brown, A.J.; Dusso, A.; Slatopolsky, E. Vitamin D. Am. J. Physiol., 1999, 277(2 Pt 2), F157-175.
18. Kato, S. The function of vitamin D receptor in vitamin D action. J. Biochem., 2000, 127(5), 717-722.
19. Nanes, M.S.; Kuno, H.; Demay, M.B.; Kurian, M.; Hendy, G.N.; DeLuca, H.F.; Titus, L.; Rubin, J. A single up-stream element confers responsiveness to 1,25-dihydroxyvitamin D3 and tumor necrosis factor-alpha in the rat osteocalcin gene. Endocrinology, 1994, 134(3), 1113-1120.
20. Lu, X.; Farmer, P.; Rubin, J.; Nanes, M.S. Integration of the NfkappaB p65 subunit into the vitamin D receptor transcriptional complex: identification of p65 domains that inhibit 1,25-dihydroxyvitamin D3-stimulated transcription. J. Cell. Biochem., 2004, 92(4), 833-848.
21. Pascussi, J.M.; Gerbal-Chaloin, S.; Drocourt, L.; Maurel, P.; Vilarem, M.J. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim. Biophys. Acta, 2003, 1619(3), 243-253.
22. Kliewer, S.A.; Moore, J.T.; Wade, L.; Staudinger, J.L.; Watson, M.A.; Jones, S.A.; McKee, D.D.; Oliver, B.B.; Willson, T.M.; Zetterstrom, R.H.; Perlmann, T.; Lehmann, J.M. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell, 1998, 92(1), 73-82.
23. Lim, Y.P.; Huang, J.D. Interplay of pregnane X receptor with other nuclear receptors on gene regulation. Drug Metab. Pharmacokinet., 2008, 23(1), 14-21.
24. Gollamudi, R.; Gupta, D.; Goel, S.; Mani, S. Novel orphan nuclear receptors-coregulator interactions controlling anti-cancer drug metabolism. Curr. Drug Metab., 2008, 9(7), 611-613.
25. Roth, A.; Looser, R.; Kaufmann, M.; Meyer, U.A. Sterol regulatory element binding protein 1 interacts with pregnane X receptor and constitutive androstane receptor and represses their target genes. Pharmacogenet. Genom., 2008, 18(4), 325-337.
26. Baes, M.; Gulick, T.; Choi, H.S.; Martinoli, M.G.; Simha, D.; Moore, D.D. A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements. Mol. Cell. Biol., 1994, 14(3), 1544-1552.
27. Pascussi, J.M.; Dvorak, Z.; Gerbal-Chaloin, S.; Assenat, E.; Maurel, P.; Vilarem, M.J. Pathophysiological factors affecting CAR gene expression. Drug Metab. Rev., 2003, 35(4), 255-268.
28. Sueyoshi, T.; Kawamoto, T.; Zelko, I.; Honkakoski, P.; Negishi, M. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J. Biol. Chem., 1999, 274(10), 6043-6046.
29. Gerbal-Chaloin, S.; Daujat, M.; Pascussi, J.M.; Pichard-Garcia, L.; Vilarem, M.J.; Maurel, P. Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J. Biol. Chem., 2002, 277(1), 209-217.
30. Goodwin, B.; Hodgson, E.; D'Costa, D.J.; Robertson, G.R.; Liddle, C. Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol. Pharmacol., 2002, 62(2), 359-365.
31. Sueyoshi, T.; Negishi, M. Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu. Rev. Pharmacol. Toxicol., 2001, 41, 123-143.
32. Pascussi, J.M.; Busson-Le Coniat, M.; Maurel, P.; Vilarem, M.J. Transcriptional analysis of the orphan nuclear receptor constitutive androstane receptor (NR1I3) gene promoter: identification of a distal glucocorticoid response element. Mol. Endocrinol., 2003, 17(1), 42-55.
33. Ding, X.; Lichti, K.; Kim, I.; Gonzalez, F.J.; Staudinger, J.L. Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor alpha, and the coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha. J. Biol. Chem., 2006, 281(36), 26540-26551.
34. Rowlands, J.C.; Gustafsson, J.A. Aryl hydrocarbon receptormediated signal transduction. Crit. Rev. Toxicol., 1997, 27(2), 109-134.
35. Hahn, M.E. Aryl hydrocarbon receptors: diversity and evolution. Chem. Biol. Interact., 2002, 141(1-2), 131-160.
36. Kikuchi, Y.; Ohsawa, S.; Mimura, J.; Ema, M.; Takasaki, C.; Sogawa, K.; Fujii-Kuriyama, Y. Heterodimers of bHLH-PAS protein fragments derived from AhR, AhRR, and Arnt prepared by co-expression in Escherichia coli: characterization of their DNA binding activity and preparation of a DNA complex. J. Biochem., 2003, 134(1), 83-90.
37. Itoh, K.; Chiba, T.; Takahashi, S.; Ishii, T.; Igarashi, K.; Katoh, Y.; Oyake, T.; Hayashi, N.; Satoh, K.; Hatayama, I.; Yamamoto, M.; Nabeshima, Y. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun., 1997, 236(2), 313-322.
38. Itoh, K.; Wakabayashi, N.; Katoh, Y.; Ishii, T.; O'Connor, T.; Yamamoto, M. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells, 2003, 8(4), 379-391.
39. McMahon, M.; Itoh, K.; Yamamoto, M.; Hayes, J.D. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J. Biol. Chem., 2003, 278(24), 21592-21600.
40. Cha, Y.N.; Heine, H.S. Comparative effects of dietary administration of 2(3)-tert-butyl-4-hydroxyanisole and 3,5-di-tertbutyl-4-hydroxytoluene on several hepatic enzyme activities in mice and rats. Cancer Res., 1982, 42(7), 2609-2615.
41. Ellis, E.M.; Slattery, C.M.; Hayes, J.D. Characterization of the rat aflatoxin B1 aldehyde reductase gene, AKR7A1. Structure and chromosomal localization of AKR7A1 as well as identification of antioxidant response elements in the gene promoter. Carcinogenesis, 2003, 24(4), 727-737.
42. Benson, A.M.; Cha, Y.N.; Bueding, E.; Heine, H.S.; Talalay, P. Elevation of extrahepatic glutathione S-transferase and epoxide hydratase activities by 2(3)-tert-butyl-4-hydroxyanisole. Cancer Res., 1979, 39(8), 2971-2977.
43. Benson, A.M.; Batzinger, R.P.; Ou, S.Y.; Bueding, E.; Cha, Y.N.; Talalay, P. Elevation of hepatic glutathione S-transferase activities and protection against mutagenic metabolites of benzo(a)pyrene by dietary antioxidants. Cancer Res., 1978, 38(12), 4486-4495.
44. Benson, A.M.; Hunkeler, M.J.; Talalay, P. Increase of NAD(P)H:quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proc. Natl. Acad. Sci. U. S. A., 1980, 77(9), 5216-5220.
45. Prestera, T.; Holtzclaw, W.D.; Zhang, Y.; Talalay, P. Chemical and molecular regulation of enzymes that detoxify carcinogens. Proc. Natl. Acad. Sci. U. S. A., 1993, 90(7), 2965-2969.
46. Alam, J.; Camhi, S.; Choi, A.M. Identification of a second region upstream of the mouse heme oxygenase-1 gene that functions as a basal level and inducer-dependent transcription enhancer. J. Biol. Chem., 1995, 270(20), 11977-11984.
47. Prestera, T.; Talalay, P. Electrophile and antioxidant regulation of enzymes that detoxify carcinogens. Proc. Natl. Acad. Sci. U. S. A., 1995, 92(19), 8965-8969.
48. Ishii, T.; Itoh, K.; Takahashi, S.; Sato, H.; Yanagawa, T.; Katoh, Y.; Bannai, S.; Yamamoto, M. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J. Biol. Chem., 2000, 275(21), 16023-16029.
49. Ishii, T.; Itoh, K.; Ruiz, E.; Leake, D.S.; Unoki, H.; Yamamoto, M.; Mann, G.E. Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal. Circ. Res., 2004, 94(5), 609-616.
50. Primiano, T.; Kensler, T.W.; Kuppusamy, P.; Zweier, J.L.; Sutter, T.R. Induction of hepatic heme oxygenase-1 and ferritin in rats by cancer chemopreventive dithiolethiones. Carcinogenesis, 1996, 17(11), 2291-2296.
51. Pietsch, E.C.; Chan, J.Y.; Torti, F.M.; Torti, S.V. Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones. J. Biol. Chem., 2003, 278(4), 2361-2369.
52. Kim, Y.C.; Yamaguchi, Y.; Kondo, N.; Masutani, H.; Yodoi, J. Thioredoxin-dependent redox regulation of the antioxidant responsive element (ARE) in electrophile response. Oncogene, 2003, 22(12), 1860-1865.
53. Zhang, J.; Svehlikova, V.; Bao, Y.; Howie, A.F.; Beckett, G.J.; Williamson, G. Synergy between sulforaphane and selenium in the induction of thioredoxin reductase 1 requires both transcriptional and translational modulation. Carcinogenesis, 2003, 24(3), 497-503.
54. Hintze, K.J.; Wald, K.A.; Zeng, H.; Jeffery, E.H.; Finley, J.W. Thioredoxin reductase in human hepatoma cells is transcriptionally regulated by sulforaphane and other electrophiles via an antioxidant response element. J. Nutr., 2003, 133(9), 2721-2727.
55. Wang, W.; Wang, S.; Howie, A.F.; Beckett, G.J.; Mithen, R.; Bao, Y. Sulforaphane, erucin, and iberin up-regulate thioredoxin reductase 1 expression in human MCF-7 cells. J. Agric. Food Chem., 2005, 53(5), 1417-1421.
56. Ciaccio, P.J.; Jaiswal, A.K.; Tew, K.D. Regulation of human dihydrodiol dehydrogenase by Michael acceptor xenobiotics. J. Biol. Chem., 1994, 269(22), 15558-15562.
57. Sherratt, P.J.; McLellan, L.I.; Hayes, J.D. Positive and negative regulation of prostaglandin E2 biosynthesis in human colorectal carcinoma cells by cancer chemopreventive agents. Biochem. Pharmacol., 2003, 66(1), 51-61.
58. Moinova, H.R.; Mulcahy, R.T. An electrophile responsive element (EpRE) regulates beta-naphthoflavone induction of the human gamma-glutamylcysteine synthetase regulatory subunit gene. Constitutive expression is mediated by an adjacent AP-1 site. J. Biol. Chem., 1998, 273(24), 14683-14689.
59. Sasaki, H.; Sato, H.; Kuriyama-Matsumura, K.; Sato, K.; Maebara, K.; Wang, H.; Tamba, M.; Itoh, K.; Yamamoto, M.; Bannai, S. Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression. J. Biol. Chem., 2002, 277(47), 44765-44771.
60. Banning, A.; Deubel, S.; Kluth, D.; Zhou, Z.; Brigelius-Flohe, R. The GI-GPx gene is a target for Nrf2. Mol. Cell. Biol., 2005, 25(12), 4914-4923.
61. Primiano, T.; Li, Y.; Kensler, T.W.; Trush, M.A.; Sutter, T.R. Identification of dithiolethione-inducible gene-1 as a leukotriene B4 12-hydroxydehydrogenase: implications for chemoprevention. Carcinogenesis, 1998, 19(6), 999-1005.
62. Primiano, T.; Kensler, T.W.; Trush, M.A.; Sutter, T.R. Induction of leukotriene B4 metabolism by cancer chemopreventive agents. Adv. Exp. Med. Biol., 1999, 469, 599-605.
63. Gonzalez, F.J. Regulation of hepatocyte nuclear factor 4 alphamediated transcription. Drug Metab. Pharmacokinet., 2008, 23(1),2-7.
64. Kamiya, A.; Inoue, Y.; Gonzalez, F.J. Role of the hepatocyte nuclear factor 4alpha in control of the pregnane X receptor during fetal liver development. Hepatology, 2003, 37(6), 1375-1384.
65. Wisely, G.B.; Miller, A.B.; Davis, R.G.; Thornquest, A.D., Jr.; Johnson, R.; Spitzer, T.; Sefler, A.; Shearer, B.; Moore, J.T.; Willson, T.M.; Williams, S.P. Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids. Structure, 2002, 10(9), 1225-1234.
66. Schroeder, F.; Huang, H.; Hostetler, H.A.; Petrescu, A.D.; Hertz, R.; Bar-Tana, J.; Kier, A.B. Stability of fatty acyl-coenzyme A thioester ligands of hepatocyte nuclear factor-4alpha and peroxisome proliferator-activated receptor-alpha. Lipids, 2005, 40(6), 559-568.
67. Gervois, P.; Torra, I.P.; Fruchart, J.C.; Staels, B. Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin. Chem. Lab. Med., 2000, 38(1), 3-11.
68. Gilde, A.J.; Van der Lee, K.A.; Willemsen, P.H.; Chinetti, G.; Van der Leij, F.R.; Van der Vusse, G.J.; Staels, B.; Van Bilsen, M. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ. Res., 2003, 92(5), 518-524.
69. Yu, S.; Rao, S.; Reddy, J.K. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr. Mol. Med., 2003, 3(6), 561-572.
70. Keller, H.; Dreyer, C.; Medin, J.; Mahfoudi, A.; Ozato, K.; Wahli, W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc. Natl. Acad. Sci. U. S. A., 1993, 90(6), 2160-2164.
71. Willson, T.M.; Brown, P.J.; Sternbach, D.D.; Henke, B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem., 2000, 43(4), 527-550.
72. Desvergne, B.; Wahli, W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev., 1999, 20(5), 649-688.
73. Venkateswaran, A.; Laffitte, B.A.; Joseph, S.B.; Mak, P.A.; Wilpitz, D.C.; Edwards, P.A.; Tontonoz, P. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. Natl. Acad. Sci. U. S. A., 2000, 97(22), 12097-12102.
74. Goodwin, B.; Hodgson, E.; Liddle, C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol.Pharmacol., 1999, 56(6), 1329-1339.
75. Mangelsdorf, D.J.; Evans, R.M. The RXR heterodimers and orphan receptors. Cell, 1995, 83(6), 841-850.
76. Meyer, U.A. Overview of enzymes of drug metabolism. J. Pharmacokinet. Biopharm., 1996, 24(5), 449-459.
77. Danielson, P.B. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr. Drug Metab., 2002, 3(6), 561-597.
78. Gonzalez, F.J.; Fernandez-Salguero, P. The aryl hydrocarbon receptor: studies using the AHR-null mice. Drug Metab. Dispos., 1998, 26(12), 1194-1198.
79. Hidestrand, M.; Oscarson, M.; Salonen, J.S.; Nyman, L.; Pelkonen, O.; Turpeinen, M.; Ingelman-Sundberg, M. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab. Dispos., 2001, 29(11), 1480-1484.
80. Honkakoski, P.; Negishi, M. Characterization of a phenobarbitalresponsive enhancer module in mouse P450 Cyp2b10 gene. J. Biol. Chem., 1997, 272(23), 14943-14949.
81. Honkakoski, P.; Zelko, I.; Sueyoshi, T.; Negishi, M. The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital- responsive enhancer module of the CYP2B gene. Mol. Cell. Biol., 1998, 18(10), 5652-5658.
82. Honkakoski, P.; Moore, R.; Washburn, K.A.; Negishi, M. Activation by diverse xenochemicals of the 51-base pair phenobarbital-responsive enhancer module in the CYP2B10 gene. Mol. Pharmacol., 1998, 53(4), 597-601.
83. Wang, H.; Faucette, S.; Sueyoshi, T.; Moore, R.; Ferguson, S.; Negishi, M.; LeCluyse, E.L. A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J. Biol. Chem., 2003, 278(16), 14146-14152.
84. Wang, H.; Faucette, S.R.; Gilbert, D.; Jolley, S.L.; Sueyoshi, T.; Negishi, M.; LeCluyse, E.L. Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes. Drug Metab. Dispos., 2003, 31(5), 620-630.
85. Pascussi, J.M.; Drocourt, L.; Gerbal-Chaloin, S.; Fabre, J.M.; Maurel, P.; Vilarem, M.J. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur. J. Biochem., 2001, 268(24), 6346-6358.
86. Guengerich, F.P. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J., 2006, 8(1), E101-111.
87. Drocourt, L.; Ourlin, J.C.; Pascussi, J.M.; Maurel, P.; Vilarem, M.J. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J.Biol.Chem., 2002, 277(28), 25125-25132.
88. Rushmore, T.H.; Kong, A.N. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr. Drug Metab., 2002, 3(5), 481-490.
89. Lieber, C.S. Cytochrome P-4502E1: its physiological and pathological role. Physiol. Rev., 1997, 77(2), 517-544.
90. Kamiyama, Y.; Matsubara, T.; Yoshinari, K.; Nagata, K.; Kamimura, H.; Yamazoe, Y. Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA. Drug Metab. Pharmacokinet., 2007, 22(4), 287-298.
91. Gellner, K.; Eiselt, R.; Hustert, E.; Arnold, H.; Koch, I.; Haberl, M.; Deglmann, C.J.; Burk, O.; Buntefuss, D.; Escher, S.; Bishop, C.; Koebe, H.G.; Brinkmann, U.; Klenk, H.P.; Kleine, K.; Meyer, U.A.; Wojnowski, L. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics, 2001, 11(2), 111-121.
92. Martinez-Jimenez, C.P.; Jover, R.; Donato, M.T.; Castell, J.V.; Gomez-Lechon, M.J. Transcriptional regulation and expression of CYP3A4 in hepatocytes. Curr. Drug Metab., 2007, 8(2), 185-194.
93. Guengerich, F.P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 1-17.
94. Stedman, C.A.; Liddle, C.; Coulter, S.A.; Sonoda, J.; Alvarez, J.G.; Moore, D.D.; Evans, R.M.; Downes, M. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc. Natl. Acad. Sci. U. S. A., 2005, 102(6), 2063-2068.
95. Thummel, K.E.; Brimer, C.; Yasuda, K.; Thottassery, J.; Senn, T.; Lin, Y.; Ishizuka, H.; Kharasch, E.; Schuetz, J.; Schuetz, E. Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol. Pharmacol., 2001, 60(6), 1399-1406.
96. Huss, J.M.; Wang, S.I.; Astrom, A.; McQuiddy, P.; Kasper, C.B. Dexamethasone responsiveness of a major glucocorticoid-inducible CYP3A gene is mediated by elements unrelated to a glucocorticoid receptor binding motif. Proc. Natl. Acad. Sci. U. S. A., 1996, 93(10), 4666-4670.
97. Hashimoto, H.; Toide, K.; Kitamura, R.; Fujita, M.; Tagawa, S.; Itoh, S.; Kamataki, T. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur. J. Biochem., 1993, 218(2), 585-595.
98. Tirona, R.G.; Lee, W.; Leake, B.F.; Lan, L.B.; Cline, C.B.; Lamba, V.; Parviz, F.; Duncan, S.A.; Inoue, Y.; Gonzalez, F.J.; Schuetz, E.G.; Kim, R.B. The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat. Med., 2003, 9(2), 220-224.
99. Okita, R.T.; Okita, J.R. Cytochrome P450 4A fatty acid omega hydroxylases. Curr. Drug Metab., 2001, 2(3), 265-281.
100. Simpson, A.E. The cytochrome P450 4 (CYP4) family. Gen. Pharmacol., 1997, 28(3), 351-359.
101. Menke, J.G.; Macnaul, K.L.; Hayes, N.S.; Baffic, J.; Chao, Y.S.; Elbrecht, A.; Kelly, L.J.; Lam, M.H.; Schmidt, A.; Sahoo, S.; Wang, J.; Wright, S.D.; Xin, P.; Zhou, G.; Moller, D.E.; Sparrow, C.P. A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a). Endocrinology, 2002, 143(7), 2548-2558.
102. Del Castillo-Olivares, A.; Gil, G. Role of FXR and FTF in bile acid-mediated suppression of cholesterol 7alpha-hydroxylase transcription. Nucleic Acids Res., 2000, 28(18), 3587-3593.
103. Molowa, D.T.; Chen, W.S.; Cimis, G.M.; Tan, C.P. Transcriptional regulation of the human cholesterol 7 alpha-hydroxylase gene. Biochemistry (Mosc.), 1992, 31(9), 2539-2544.
104. Staudinger, J.L.; Goodwin, B.; Jones, S.A.; Hawkins-Brown, D.; MacKenzie, K.I.; LaTour, A.; Liu, Y.; Klaassen, C.D.; Brown, K.K.; Reinhard, J.; Willson, T.M.; Koller, B.H.; Kliewer, S.A. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. USA, 2001, 98(6), 3369-3374.
105. Goodwin, B.; Jones, S.A.; Price, R.R.; Watson, M.A.; McKee, D.D.; Moore, L.B.; Galardi, C.; Wilson, J.G.; Lewis, M.C.; Roth, M.E.; Maloney, P.R.; Willson, T.M.; Kliewer, S.A. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell, 2000, 6(3), 517-526.
106. Ponugoti, B.; Fang, S.; Kemper, J.K. Functional interaction of hepatic nuclear factor-4 and peroxisome proliferator-activated receptor-gamma coactivator 1alpha in CYP7A1 regulation is inhibited by a key lipogenic activator, sterol regulatory elementbinding protein-1c. Mol. Endocrinol., 2007, 21(11), 2698-2712.
107. Morgan, E.T. Regulation of cytochrome p450 by inflammatory mediators: why and how?, Drug Metab. Dispos., 2001, 29(3), 207-212.
108. Muntane-Relat, J.; Ourlin, J.C.; Domergue, J.; Maurel, P. Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology, 1995, 22(4 Pt 1), 1143-1153.
109. Jover, R.; Bort, R.; Gomez-Lechon, M.J.; Castell, J.V. Downregulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J., 2002, 16(13), 1799-1801.
110. Tian, Y.; Rabson, A.B.; Gallo, M.A. Ah receptor and NF-kappaB interactions: mechanisms and physiological implications. Chem. Biol. Interact., 2002, 141(1-2), 97-115.
111. Ke, S.; Rabson, A.B.; Germino, J.F.; Gallo, M.A.; Tian, Y. Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide. J. Biol. Chem., 2001, 276(43), 39638-39644.
112. Leite, R.S.; Brown, A.G.; Strauss, J.F. Tumor necrosis factor-alpha suppresses the expression of steroid receptor coactivator-1 and -2: a possible mechanism contributing to changes in steroid hormone responsiveness. FASEB J., 2004, 18(12), 1418-1420.
113. Vogel, C.F.; Sciullo, E.; Li, W.; Wong, P.; Lazennec, G.; Matsumura, F. RelB, a new partner of aryl hydrocarbon receptormediated transcription. Mol. Endocrinol., 2007, 21(12), 2941-2955.
114. Gu, X.; Ke, S.; Liu, D.; Sheng, T.; Thomas, P.E.; Rabson, A.B.; Gallo, M.A.; Xie, W.; Tian, Y. Role of NF-kappa B in regulation of PXR-mediated gene expression: A mechanism for the suppression of cytochrome P450 3A4 by proinflammatory agents. J. Biol. Chem., 2006, 281(26), 17882-17889.
115. Na, S.Y.; Kang, B.Y.; Chung, S.W.; Han, S.J.; Ma, X.; Trinchieri, G.; Im, S.Y.; Lee, J.W.; Kim, T.S. Retinoids inhibit interleukin-12 production in macrophages through physical associations of retinoid X receptor and NFkappaB. J. Biol. Chem., 1999, 274(12), 7674-7680.
116. Beigneux, A.P.; Moser, A.H.; Shigenaga, J.K.; Grunfeld, C.; Feingold, K.R. The acute phase response is associated with retinoid X receptor repression in rodent liver. J. Biol. Chem., 2000, 275(21), 16390-16399.
117. Pascussi, J.M.; Gerbal-Chaloin, S.; Pichard-Garcia, L.; Daujat, M.; Fabre, J.M.; Maurel, P.; Vilarem, M.J. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem. Biophys. Res. Commun., 2000, 274(3), 707-713.
118. Teng, S.; Piquette-Miller, M. The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice. J. Pharmacol. Exp. Ther., 2005, 312(2), 841-848.
119. Caldenhoven, E.; Liden, J.; Wissink, S.; Van de Stolpe, A.; Raaijmakers, J.; Koenderman, L.; Okret, S.; Gustafsson, J.A.; Van der Saag, P.T. Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol. Endocrinol., 1995, 9(4), 401-412.
120. Assenat, E.; Gerbal-Chaloin, S.; Maurel, P.; Vilarem, M.J.; Pascussi, J.M. Is nuclear factor kappa-B the missing link between inflammation, cancer and alteration in hepatic drug metabolism in patients with cancer?. Eur. J. Cancer, 2006, 42(6), 785-792.
121. Delerive, P.; De Bosscher, K.; Besnard, S.; Vanden Berghe, W.; Peters, J.M.; Gonzalez, F.J.; Fruchart, J.C.; Tedgui, A.; Haegeman, G.; Staels, B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem., 1999, 274(45), 32048-32054.
122. Wang, Y.; Moser, A.H.; Shigenaga, J.K.; Grunfeld, C.; Feingold, K.R. Downregulation of liver X receptor-alpha in mouse kidney and HK-2 proximal tubular cells by LPS and cytokines. J. Lipid Res., 2005, 46(11), 2377-2387.
123. Kim, O.S.; Lee, C.S.; Joe, E.H.; Jou, I. Oxidized low density lipoprotein suppresses lipopolysaccharide-induced inflammatory responses in microglia: oxidative stress acts through control of inflammation. Biochem. Biophys. Res. Commun., 2006, 342(1), 9-18.
124. Wang, Y.D.; Chen, W.D.; Wang, M.; Yu, D.; Forman, B.M.; Huang, W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology, 2008, 48(5), 1632-1643.
125. Lee, S.H.; Wang, X.; DeJong, J. Functional interactions between an atypical NF-kappaB site from the rat CYP2B1 promoter and the transcriptional repressor RBP-Jkappa/CBF1. Nucleic Acids Res., 2000, 28(10), 2091-2098.
126. Morgan, E.T.; Li-Masters, T.; Cheng, P.Y. Mechanisms of cytochrome P450 regulation by inflammatory mediators. Toxicology, 2002, 181-182, 207-210.
127. Abdulla, D.; Goralski, K.B.; Del Busto Cano, E.G.; Renton, K.W. The signal transduction pathways involved in hepatic cytochrome P450 regulation in the rat during a lipopolysaccharide-induced model of central nervous system inflammation. Drug Metab. Dispos., 2005, 33(10), 1521-1531.
128. Peng, H.M.; Coon, M.J. Promoter function and the role of cytokines in the transcriptional regulation of rabbit CYP2E1 and CYP2E2. Arch. Biochem. Biophys., 2000, 382(1), 129-137.
129. Saito, T.; Takahashi, Y.; Hashimoto, H.; Kamataki, T. Novel transcriptional regulation of the human CYP3A7 gene by Sp1 and Sp3 through nuclear factor kappa B-like element. J. Biol. Chem., 2001, 276(41), 38010-38022.
130. Owuor, E.D.; Kong, A.N. Antioxidants and oxidants regulated signal transduction pathways. Biochem. Pharmacol., 2002, 64(5-6), 765-770.
131. Yu, R.; Chen, C.; Mo, Y.Y.; Hebbar, V.; Owuor, E.D.; Tan, T.H.; Kong, A.N. Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism. J. Biol. Chem., 2000, 275(51), 39907-39913.
132. Wattenberg, L.W. Inhibition of chemical carcinogen-induced pulmonary neoplasia by butylated hydroxyanisole. J. Natl. Cancer Inst., 1973, 50(6), 1541-1544.
133. Wattenberg, L.W.; Coccia, J.B.; Lam, L.K. Inhibitory effects of phenolic compounds on benzo(a)pyrene-induced neoplasia. Cancer Res., 1980, 40(8 Pt 1), 2820-2823.
134. King, M.M.; McCay, P.B. Modulation of tumor incidence and possible mechanisms of inhibition of mammary carcinogenesis by dietary antioxidants. Cancer Res., 1983, 43(5 Suppl), 2485s-2490s.
135. Sparnins, V.L.; Venegas, P.L.; Wattenberg, L.W. Glutathione Stransferase activity: enhancement by compounds inhibiting chemical carcinogenesis and by dietary constituents. J. Natl. Cancer Inst., 1982, 68(3), 493-496.
136. Yu, R.; Jiao, J.J.; Duh, J.L.; Gudehithlu, K.; Tan, T.H.; Kong, A.N. Activation of mitogen-activated protein kinases by green tea polyphenols: potential signaling pathways in the regulation of antioxidant-responsive element-mediated phase II enzyme gene expression. Carcinogenesis, 1997, 18(2), 451-456.
137. Yu, R.; Tan, T.H.; Kong, A.N. Butylated hydroxyanisole and its metabolite tert-butylhydroquinone differentially regulate mitogenactivated protein kinases. The role of oxidative stress in the activation of mitogen-activated protein kinases by phenolic antioxidants. J. Biol. Chem., 1997, 272(46), 28962-28970.
138. Chen, C.; Yu, R.; Owuor, E.D.; Kong, A.N. Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch. Pharm. Res., 2000, 23(6), 605-612.
139. Yu, R.; Mandlekar, S.; Lei, W.; Fahl, W.E.; Tan, T.H.; Kong, A.N. p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens. J. Biol. Chem., 2000, 275(4), 2322-2327.
140. Kang, K.W.; Lee, S.J.; Park, J.W.; Kim, S.G. Phosphatidylinositol 3-kinase regulates nuclear translocation of NF-E2-related factor 2 through actin rearrangement in response to oxidative stress. Mol. Pharmacol., 2002, 62(5), 1001-1010.
141. Huang, H.C.; Nguyen, T.; Pickett, C.B. Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2-related factor 2. Proc. Natl. Acad. Sci. U. S. A., 2000, 97(23), 12475-12480.
142. Cullinan, S.B.; Diehl, J.A. PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. J. Biol. Chem., 2004, 279(19), 20108-20117.
143. Wakabayashi, N.; Dinkova-Kostova, A.T.; Holtzclaw, W.D.; Kang, M.I.; Kobayashi, A.; Yamamoto, M.; Kensler, T.W.; Talalay, P. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc. Natl. Acad. Sci. U. S. A., 2004, 101(7), 2040-2045.
144. Bock, K.W.; Gschaidmeier, H.; Heel, H.; Lehmkoster, T.; Munzel, P.A.; Raschko, F.; Bock-Hennig, B. AH receptor-controlled transcriptional regulation and function of rat and human UDPglucuronosyltransferase isoforms. Adv. Enzyme Regul., 1998, 38, 207-222.
145. Hankinson, O. The aryl hydrocarbon receptor complex. Annu. Rev. Pharmacol. Toxicol., 1995, 35, 307-340.
146. Schmidt, J.V.; Bradfield, C.A. Ah receptor signaling pathways. Annu. Rev. Cell Dev. Biol., 1996, 12, 55-89.
147. Rushmore, T.H.; King, R.G.; Paulson, K.E.; Pickett, C.B. Regulation of glutathione S-transferase Ya subunit gene expression: identification of a unique xenobiotic-responsive element controlling inducible expression by planar aromatic compounds. Proc. Natl. Acad. Sci. U. S. A., 1990, 87(10), 3826-3830.
148. Bock, K.W.; Frohling, W.; Remmer, H.; Rexer, B. Effects of phenobarbital and 3-methylcholanthrene on substrate specificity of rat liver microsomal UDP-glucuronyltransferase. Biochim. Biophys. Acta, 1973, 327(1), 46-56.
149. Sugatani, J.; Kojima, H.; Ueda, A.; Kakizaki, S.; Yoshinari, K.; Gong, Q.H.; Owens, I.S.; Negishi, M.; Sueyoshi, T. The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR. Hepatology, 2001, 33(5), 1232-1238.
150. Sugatani, J.; Nishitani, S.; Yamakawa, K.; Yoshinari, K.; Sueyoshi, T.; Negishi, M.; Miwa, M. Transcriptional regulation of human UGT1A1 gene expression: activated glucocorticoid receptor enhances constitutive androstane receptor/pregnane X receptormediated UDP-glucuronosyltransferase 1A1 regulation with glucocorticoid receptor-interacting protein 1. Mol. Pharmacol., 2005, 67(3), 845-855.
151. Buckley, D.B.; Klaassen, C.D. Induction of mouse UDPglucuronosyltransferase mRNA expression in liver and intestine by activators of aryl-hydrocarbon receptor, constitutive androstane receptor, pregnane X receptor, peroxisome proliferator-activated receptor alpha, and nuclear factor erythroid 2-related factor 2. Drug Metab. Dispos., 2009, 37(4), 847-856.
152. Barbier, O.; Torra, I.P.; Sirvent, A.; Claudel, T.; Blanquart, C.; Duran-Sandoval, D.; Kuipers, F.; Kosykh, V.; Fruchart, J.C.; Staels, B. FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology, 2003, 124(7), 1926-1940.
153. Sonoda, J.; Xie, W.; Rosenfeld, J.M.; Barwick, J.L.; Guzelian, P.S.; Evans, R.M. Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc. Natl. Acad. Sci. U. S. A., 2002, 99(21), 13801-13806.
154. Fang, H.L.; Strom, S.C.; Ellis, E.; Duanmu, Z.; Fu, J.; Duniec-Dmuchowski, Z.; Falany, C.N.; Falany, J.L.; Kocarek, T.A.; Runge-Morris, M. Positive and negative regulation of human hepatic hydroxysteroid sulfotransferase (SULT2A1) gene transcription by rifampicin: roles of hepatocyte nuclear factor 4alpha and pregnane X receptor. J. Pharmacol. Exp. Ther., 2007, 323(2), 586-598.
155. Barbier, O.; Villeneuve, L.; Bocher, V.; Fontaine, C.; Torra, I.P.; Duhem, C.; Kosykh, V.; Fruchart, J.C.; Guillemette, C.; Staels, B. The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J. Biol. Chem., 2003, 278(16), 13975-13983.
156. Mackenzie, P.I.; Gregory, P.A.; Gardner-Stephen, D.A.; Lewinsky, R.H.; Jorgensen, B.R.; Nishiyama, T.; Xie, W.; Radominska-Pandya, A. Regulation of UDP glucuronosyltransferase genes. Curr. Drug Metab., 2003, 4(3), 249-257.
157. Mackenzie, P.I.; Rodbourn, L. Organization of the rat UDPglucuronosyltransferase, UDPGTr-2, gene and characterization of its promoter. J. Biol. Chem., 1990, 265(19), 11328-11332.
158. Hansen, A.J.; Lee, Y.H.; Sterneck, E.; Gonzalez, F.J.; Mackenzie, P.I. C/EBPalpha is a regulator of the UDP glucuronosyltransferase UGT2B1 gene. Mol. Pharmacol., 1998, 53(6), 1027-1033.
159. Gregory, P.A.; Mackenzie, P.I. The homeodomain Pbx2-Prep1 complex modulates hepatocyte nuclear factor 1alpha-mediated activation of the UDP-glucuronosyltransferase 2B17 gene. Mol. Pharmacol., 2002, 62(1), 154-161.
160. Turgeon, D.; Carrier, J.S.; Levesque, E.; Beatty, B.G.; Belanger, A.; Hum, D.W. Isolation and characterization of the human UGT2B15 gene, localized within a cluster of UGT2B genes and pseudogenes on chromosome 4. J. Mol. Biol., 2000, 295(3), 489-504.
161. Geick, A.; Eichelbaum, M.; Burk, O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem., 2001, 276(18), 14581-14587.
162. Synold, T.W.; Dussault, I.; Forman, B.M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med., 2001, 7(5), 584-590.
163. Kullak-Ublick, G.A.; Becker, M.B. Regulation of drug and bile salt transporters in liver and intestine. Drug Metab. Rev., 2003, 35(4), 305-317.
164. Frank, C.; Makkonen, H.; Dunlop, T.W.; Matilainen, M.; Vaisanen, S.; Carlberg, C. Identification of pregnane X receptor binding sites in the regulatory regions of genes involved in bile acid homeostasis. J. Mol. Biol., 2005, 346(2), 505-519.
165. Guo, G.L.; Staudinger, J.; Ogura, K.; Klaassen, C.D. Induction of rat organic anion transporting polypeptide 2 by pregnenolone-16alpha-carbonitrile is via interaction with pregnane X receptor. Mol. Pharmacol., 2002, 61(4), 832-839.
166. Staudinger, J.; Liu, Y.; Madan, A.; Habeebu, S.; Klaassen, C.D. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab. Dispos., 2001, 29(11), 1467-1472.
167. Staudinger, J.L.; Madan, A.; Carol, K.M.; Parkinson, A. Regulation of drug transporter gene expression by nuclear receptors. Drug Metab. Dispos., 2003, 31(5), 523-527.
168. Kast, H.R.; Goodwin, B.; Tarr, P.T.; Jones, S.A.; Anisfeld, A.M.; Stoltz, C.M.; Tontonoz, P.; Kliewer, S.; Willson, T.M.; Edwards, P.A. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem., 2002, 277(4), 2908-2915.
169. Inokuchi, A.; Hinoshita, E.; Iwamoto, Y.; Kohno, K.; Kuwano, M.; Uchiumi, T. Enhanced expression of the human multidrug resistance protein 3 by bile salt in human enterocytes. A transcriptional control of a plausible bile acid transporter. J. Biol. Chem., 2001, 276(50), 46822-46829.
170. Ananthanarayanan, M.; Balasubramanian, N.; Makishima, M.; Mangelsdorf, D.J.; Suchy, F.J. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem., 2001, 276(31), 28857-28865.
171. Grober, J.; Zaghini, I.; Fujii, H.; Jones, S.A.; Kliewer, S.A.; Willson, T.M.; Ono, T.; Besnard, P. Identification of a bile acidresponsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer. J. Biol. Chem., 1999, 274(42), 29749-29754.
172. Schuetz, E.G.; Strom, S.; Yasuda, K.; Lecureur, V.; Assem, M.; Brimer, C.; Lamba, J.; Kim, R.B.; Ramachandran, V.; Komoroski, B.J.; Venkataramanan, R.; Cai, H.; Sinal, C.J.; Gonzalez, F.J.; Schuetz, J.D. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J. Biol. Chem., 2001, 276(42), 39411-39418.
173. Takikawa, H. Hepatobiliary transport of bile acids and organic anions. J. Hepatobiliary. Pancreat. Surg., 2002, 9(4), 443-447.
174. Denson, L.A.; Sturm, E.; Echevarria, W.; Zimmerman, T.L.; Makishima, M.; Mangelsdorf, D.J.; Karpen, S.J. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology, 2001, 121(1), 140-147.
175. Kok, T.; Bloks, V.W.; Wolters, H.; Havinga, R.; Jansen, P.L.; Staels, B.; Kuipers, F. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem. J, 2003, 369(Pt3), 539-547.
176. Qadri, I.; Iwahashi, M.; Kullak-Ublick, G.A.; Simon, F.R. Hepatocyte nuclear factor (HNF) 1 and HNF4 mediate hepatic multidrug resistance protein 2 up-regulation during hepatitis C virus gene expression. Mol. Pharmacol., 2006, 70(2), 627-636.